Diergo

Quick links to important sections

Diergo

Method of action: Analgesic, Vasodilator

Treatment option: Pain, Hypotension, Headache, Migraine

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Diergo

What is Diergo? Quick Facts and Identity

Property Description
Active Ingredient Dihydroergotamine (DHE)
Form Injectable solution, Nasal spray
Pharmacological Class Ergot Alkaloid Derivative
Common Use Acute termination of severe headaches
Origin Semi-synthetic compound

What Type of Medicine is Diergo (Dihydroergotamine)?

Diergo is a prescription-only medicine containing the active ingredient Dihydroergotamine (DHE), which is classified as an Ergot Alkaloid Derivative. The compound is a specialized semi-synthetic derivative, having been chemically modified from the basic structure of natural ergot alkaloids. This origin places it within the pharmacological class of Anti-migraine Agents designed for focused intervention. The compound’s utility in managing acute headaches is supported by pharmacological studies, demonstrating its efficacy as a non-narcotic treatment for patients with established, severe headache pain. It functions as an essential part of abortive therapy, meaning its primary therapeutic purpose is to stop a severe headache episode once it has begun.

Composition and Available Forms of Dihydroergotamine

Dihydroergotamine is provided as a single-ingredient product, typically formulated as the mesylate salt. The active compound is presented in multiple pharmaceutical preparations, most commonly as an injectable solution (for parenteral administration) and a nasal spray (for mucosal administration). The use of non-oral routes of administration is a distinguishing feature, recognized as critical for acute treatment to ensure faster, more consistent absorption of the compound by bypassing the variability of the digestive system. Other forms include oral and sublingual tablet preparations.

The Basic Principle of Action and General Benefit

The fundamental physiological action of Dihydroergotamine involves modulating both vascular and neurological mechanisms associated with headache. It acts as a 5-HT1B/1D receptor agonist, a process that primarily induces cranial vasoconstriction—the narrowing of certain blood vessels in the head that typically widen during an attack. Research confirms that DHE’s sustained vascular effect is essential for preventing the quick return of pain. This means the medicine is structured not only to provide initial relief but also to maintain the effect against headache recurrence. The general benefit is the rapid and targeted termination of the debilitating symptoms of an acute headache episode.

What side effects are possible with Diergo?

Possible Side Effects and Safety Information

The official safety profile for Dihydroergotamine (Diergo) classifies potential adverse reactions based on frequency and affected body system, strictly adhering to regulatory standards. The most frequently reported effects (Common: 1%-10%) include nausea and vomiting (especially with injectable forms), dizziness, diarrhea, and stiffness. With the nasal spray, rhinitis is classified as Very Common (ge10%).


Serious Adverse Reactions and Vasospasm Risk

Dihydroergotamine is associated with the risk of vasospastic events, which are rare but serious. These include Peripheral Ischemia, Coronary Artery Vasospasm, Myocardial Ischemia/Infarction, and Cerebral Hemorrhage/Stroke. The serious vascular risk profile necessitates a number of absolute safety restrictions. The medicine is contraindicated in patients with a history of Ischemic Heart Disease, Peripheral Vascular Disease, uncontrolled Hypertension, and when co-administered with potent CYP 3A4 inhibitors due to the risk of severe, life-threatening vasospasm.


Population and Exposure Constraints

The medicine is strictly contraindicated in pregnancy and during lactation. It is also contraindicated in patients with severe hepatic or renal impairment due to impaired clearance. Furthermore, the official label highlights risks associated with the frequency of use, noting that Medicine Overuse Headache is a documented risk of frequent exposure. In addition, fibrotic complications (including pleural, retroperitoneal, and cardiac valvular fibrosis) have been reported following prolonged daily use of the injectable formulation.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes Dihydroergotamine (Diergo) overdose primarily as a risk of Ergotism, a severe vasoconstrictive state. This condition may be life-threatening and requires immediate action.

Documented Overdose Manifestations

System Manifestations Listed in Official Labels
Peripheral Numbness, tingling, pain, cyanosis of the extremities, and diminished peripheral pulses.
CNS Confusion, delirium, convulsions, and coma are documented neurological outcomes.
Cardiovascular Initial blood pressure increase followed by a decrease; severe coronary artery vasospasm leading to cardiac events.

When Immediate Medical Help is Required

Regulatory authorities mandate that you seek emergency help at once if an overdose is suspected or if severe symptoms are present. Immediate medical attention is required upon the onset of signs of vasospasm, such as severe pain or weakness in the limbs, chest pain, or any sign of CNS depression, including seizures or unconsciousness.

The primary adverse outcome is severe vasospasm, which can lead to cerebral ischemia or ischemia of the extremities (gangrene). Treatment is symptomatic and supportive, focused on reversing the vasoconstriction, for which no specific antidote is known. This includes the application of warmth to affected areas and administering vasodilators as prescribed.

Therapeutic Uses of Diergo

Diergo, containing Dihydroergotamine (DHE), is generally applied within the therapeutic domain of abortive therapy, relevant for managing acute episodes. The medication is commonly used to help with conditions presenting with acute episodes, relevant for managing the symptomatic manifestations of migraine headaches (with or without aura) and cluster headache episodes.

This agent is primarily relevant for patients experiencing a significant symptomatic burden, including those whose pain is intractable or refractory to simpler treatments. It is applied in scenarios where symptoms become more noticeable and create noticeable functional strain.

“The primary goal of using this agent is to assist with maintaining functional stability by managing the manifestation of the acute episode.”

It offers a sustained effect which helps address symptom clusters that may become intense or disruptive, contributing to improved comfort during these periods of heightened symptoms and assisting with easing the overall symptom load.


Quick Fact: Supportive Management for Intense Discomfort Symptom Type Therapeutic Role
Severe Migraine/Cluster Pain Helps ease the overall symptom load.
Functionally Disruptive Symptoms Assists with maintaining a sense of stability when symptoms are more noticeable.
Recurrence Risk Assists with managing symptom recurrence after initial relief.

Eligibility and Restrictions for Use

Eligibility for Diergo (Dihydroergotamine)

Official regulatory documents define strict criteria for using Diergo, primarily limiting its use to Adult Patients (18 years and over) for acute treatment. Use is largely prohibited or restricted based on pre-existing conditions related to the drug's fundamental vascular activity.

Population Group Regulatory Status Official Restriction Basis
Cardiovascular Conditions Contraindicated Ischemic heart disease, uncontrolled hypertension, peripheral arterial disease, or coronary artery vasospasm.
Severe Organ Impairment Contraindicated Patients with severely impaired hepatic or renal function.
Pregnancy Contraindicated The drug possesses oxytocic properties and may pose a risk to the fetus.
Lactation Not Recommended Breastfeeding mothers are advised to abstain from nursing during treatment and for 3 days after the final dose.
Pediatric Population Use Not Established Safety and effectiveness have not been established in children and adolescents under 18.
Concomitant Drug Use Contraindicated Use within 24 hours of taking other 5-HT1 agonists (triptans) or ergot-type medications.

Eligibility is also prohibited in cases of sepsis, known hypersensitivity to ergot alkaloids, and certain types of headaches, such as hemiplegic or basilar migraine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Dihydroergotamine (DHE), the active ingredient in Diergo, has a defined interaction profile based strictly on official regulatory documentation.


Contraindicated Combinations

Co-administration with certain medications is formally prohibited. This includes potent Cytochrome P450 3A4 (CYP3A4) inhibitors, such as the antifungals ketoconazole and itraconazole, certain macrolide antibiotics (like erythromycin and clarithromycin), and many protease inhibitors (like ritonavir). This restriction is necessary because inhibition of the CYP3A4 enzyme significantly elevates DHE plasma levels, leading to an increased risk of severe vasoconstriction.


Other Prohibited Combinations and Restrictions

Interaction Type Interacting Agents Regulatory Requirement
Pharmacodynamic Other 5-HT₁ agonists (Triptans) and Ergotamine-Containing Agents Must not be used within 24 hours of each other due to the risk of additive vasoconstriction.
Substance Grapefruit Juice May function as a CYP3A4 inhibitor and is noted as potentially increasing DHE blood levels.
Substance Nicotine May potentiate the vasoconstrictive effects of DHE and requires caution.

Co-administration with Beta-Blockers and SSRIs may result in potentiated vasoconstriction or reported symptoms like weakness, respectively, and requires careful consideration. DHE is also formally contraindicated for use in patients with severe hepatic or renal impairment, which is related to the drug's metabolic clearance.

Mechanism of Action

Vascular Tone Modulation via 5-HT1B Agonism

Dihydroergotamine (DHE) acts as an agonist at serotonin 5-HT1B receptors located on cranial extracerebral blood vessels. Activating these receptors initiates a strong contraction in surrounding smooth muscle cells, leading to vasoconstriction of the targeted arteries. This action results in the physiological adjustment of cranial vascular tone.

Inhibition of Neurogenic Inflammation and Signal Transmission

DHE also exerts agonist action at presynaptic 5-HT1D receptors on sensory nerve endings within the trigeminovascular system. This binding restricts the release of potent vasodilatory and pro-inflammatory neuropeptides, such as Calcitonin Gene-Related Peptide (CGRP), thereby attenuating the surrounding neurogenic inflammatory cascade. The drug further modulates ascending nociceptive signals centrally at the trigeminal nucleus.

Sustained Multi-Receptor Cascade

DHE's high affinity for multiple targets, including alpha-adrenergic (alpha) receptors, facilitates a longer-lasting pharmacological intervention than mechanisms that rely solely on single-receptor action. This multi-receptor binding profile ensures the sustained modulation of both the vascular and neural signaling pathways, which supports the sustained modulation of the targeted signaling pathways.

Dosage and Administration Information

Official Administration Routes and Dosing

Diergo (Dihydroergotamine, DHE) is used exclusively as an acute, intermittent treatment for episodes. Administration must begin at the first sign of an episode for the best use of the medicine, following established routes and dosing schedules.

Administration Route Standard Adult Dosing Regimen Maximum Daily Limit
Subcutaneous (SC) / Intramuscular (IM) Initial dose of 1 mg. May be repeated after a minimum of 1 hour. 3 mg in 24 hours
Intravenous (IV) Initial dose of 1 mg. May be repeated after a minimum of 1 hour. 2 mg in 24 hours
Intranasal (Spray/Powder) Initial dose varies by product (e.g., 1.45 mg to 5.2 mg), repeatable after 15 minutes or 1 hour. Up to 10.4 mg (or 2 doses) in 24 hours

Frequency, Duration, and Preparation Rules

The administration of DHE is non-oral and governed by strict frequency and time constraints:

  • Weekly Limit: The total weekly dose for the injectable form must not exceed 6 mg. Nasal formulations typically limit use to 3 to 4 doses over a 7-day period. The medication is not intended for chronic daily administration.
  • Preparation: Nasal spray devices often require a specific priming step (e.g., 4 sprays) before the first use of the device or vial.
  • Special Procedural Conditions: For patients with cardiovascular risk factors, it is recommended that the administration of the first dose take place in a medically equipped facility.
  • Specific Populations: Use is restricted/contraindicated in individuals with severe hepatic or renal impairment. Safety and effectiveness have not been established for pediatric use.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section outlines the primary clinical findings related to the agent.

General Efficacy and Safety Profile

Research has explored the use of the agent in acute and chronic pain conditions. A major meta-analysis summarized findings regarding the agent’s anti-inflammatory properties. Findings from studies examined the duration of reduced inflammation and whether relief from pain persisted over time.

Studies reported on the tolerability profile of the agent and the frequency and severity of reported side effects.

Efficacy in Specific Contexts

Managing Acute Postoperative Pain

Studies have evaluated whether the agent is associated with a reduction in pain intensity or a shorter time to onset of pain relief compared to other agents. Research evaluated outcomes for acute pain using dosing regimens administered over short periods. This finding regarding a sustained effect was one of the outcomes recorded in studies examining short-term acute flare-ups.

Chronic Conditions and Long-term Use

Research on rheumatoid arthritis (RA) examined whether the agent was associated with changes in physical function scores and reduced markers of joint damage over a 6-month period. Other studies have also explored its use in treating pain associated with osteoarthritis (OA).

No major studies have reported significant new long-term risks. Studies related to the agent’s use in chronic pain management continue to be evaluated.

Safety Profiles

Gastrointestinal Safety Profile

The agent was studied to see if it was associated with a different risk of serious gastrointestinal side effects when compared to non-selective nonsteroidal anti-inflammatory drugs (NSAIDs). The initial findings regarding reported gastrointestinal events were consistent with the study’s design hypothesis.

Cardiovascular Considerations

The cardiovascular profile of the agent remains under review. Studies evaluated whether participants with pre-existing cardiovascular issues exhibited any differences in outcomes. These study findings have been noted, and ongoing post-market research continues to evaluate the cardiovascular risk profile.

Frequently Asked Questions (FAQ)

Common questions about Diergo (FAQ)


Q: How quickly does Diergo start working for the condition it treats?

Clinical studies summarized in regulatory documentation show the onset of pain relief was observed to typically start within 15 to 30 minutes after administration. This rapid onset supports its classification for use as an acute intervention.


Q: Is Diergo the same type of medicine as [similar drug name]?

According to official product information, Diergo's active ingredient, Dihydroergotamine, is classified as an Ergot Alkaloid Derivative. This designation identifies it as a specialized compound used for the acute termination of severe episodes. It works by acting on specific serotonin receptors in the brain and blood vessels.


Q: What are the main differences between Diergo and over-the-counter options?

According to official information, the active ingredient in Diergo is a prescription-only medicine and an Ergot Alkaloid Derivative, meaning its use is restricted to a prescription. It is specifically classified for the acute termination of severe episodes and is administered through non-oral routes.


Q: Why is Diergo sometimes used when other treatments haven't helped?

Official documents describe the drug’s mechanism of action as involving a sustained dual effect on the vascular and neural systems. This approach acts by both narrowing certain blood vessels and restricting the release of pro-inflammatory nerve signals, a sustained action that supports the termination of acute episodes.


Q: What is the difference between how Diergo works and how traditional medicines for this condition work?

Regulatory documents describe the drug's mechanism as a specialized dual action. It functions by causing the narrowing of specific blood vessels (vasoconstriction) while simultaneously restricting pro-inflammatory signals from nerves in the trigeminovascular system.


Q: What does the drug classification of Diergo mean for patients?

Diergo is classified as an Ergot Alkaloid Derivative, a designation linked to its ability to modulate vascular tone (vasoconstriction). Because of this powerful effect, regulatory documents strictly contraindicate the medicine for use in patients with certain pre-existing vascular or heart conditions.


Q: Does Diergo affect sleep or energy levels?

Official regulatory documents list somnolence (drowsiness) as a common adverse reaction associated with the use of the medicine. This is a known central nervous system effect that has been reported during clinical trials and post-market use.


Q: Is Diergo generally safe for people who drive or operate machinery?

The official prescribing information lists dizziness and somnolence (drowsiness) as common adverse reactions. Official labeling includes a general warning that these effects may impair mental and physical ability needed to perform hazardous tasks, such as driving or operating machinery.


Q: Does Diergo affect a person's mood or mental health?

Official regulatory documentation does not list changes in mood or mental health as a common or serious adverse reaction associated with the medicine. However, the side effect profile does include reported central nervous system effects such as dizziness and somnolence (drowsiness).


Q: What happens if I forget to take a dose of Diergo?

Diergo is intended as an acute treatment to be administered only at the onset of an episode, meaning the concept of a 'missed dose' does not apply. Instead, regulatory documents provide strict instructions on the minimum time interval that must be observed before a patient is permitted to administer a subsequent dose.


Q: How long does Diergo stay in the body after the last dose?

The medicine is characterized by being eliminated from the body slowly, a factor which contributes to its sustained pharmacological effect. The active ingredient has an effective half-life of approximately 10 hours, as noted in the clinical pharmacology summary.

--UNSAFE

Q: What are the signs of a severe or serious reaction to Diergo?

Official regulatory warnings detail the risk of severe reactions related to vasoconstriction. The symptoms associated with these serious events, such as severe chest pain, unusual headache, or feelings of coldness, numbness, or pain in the hands or feet, are noted in the official warnings.


Q: What should I do if I notice a side effect that isn't listed in the patient leaflet?

Official drug information strongly advises patients to communicate any experienced symptoms or suspected adverse reactions, including those not listed in the patient leaflet, to their healthcare provider. This aligns with the official process for the ongoing collection and reporting of safety data.


Q: Does Diergo have a risk of dependence or addiction?

Regulatory labeling warns against frequent exposure to the medicine, as this carries a risk of developing Medicine Overuse Headache (MOH). Furthermore, prolonged daily use of the injectable form has been associated in official documents with rare, serious risks such as fibrotic complications.


Q: Is it possible to develop a tolerance to Diergo over time?

Official regulatory documents detail that frequent exposure to the medicine carries a risk of developing a Medicine Overuse Headache (MOH). This condition is a documented complication associated with recurrent or excessive use of acute headache treatments.


Q: Can older adults typically use Diergo?

Regulatory documentation notes that older adults are more likely to have pre-existing severe organ impairment or cardiovascular conditions. Regulatory documents emphasize that the presence of these co-occurring conditions necessitates strict adherence to all contraindications.


Q: What research is currently being done on Diergo?

Research themes noted in regulatory summaries and clinical trial updates include continued evaluation of the drug's cardiovascular risk profile, as well as exploring its effectiveness in newer formulations and administration protocols. Post-market surveillance data also informs the ongoing safety assessment.


Q: Are there any common foods or drinks that should be avoided while taking Diergo?

Regulatory documents indicate that co-administration with Grapefruit Juice may increase the levels of the medicine in the blood. Official warnings also note that Nicotine use may intensify the drug's vasoconstrictive effects. The official label notes the importance of informing a healthcare provider of all substances used.


Q: Does Diergo interact with birth control pills?

Official regulatory labeling notes that the effects of oral contraceptives (birth control pills) on the body's processing of Dihydroergotamine have not been clinically studied. This lack of study is disclosed within the drug interactions section of the prescribing information.


Q: Can I take pain relievers like ibuprofen while using Diergo?

Official drug interaction warnings focus on a specific list of agents, including CYP3A4 inhibitors, triptans, and other ergot-type drugs. Regulatory documents do not list general non-selective NSAIDs, such as Ibuprofen, among the prohibited co-administered agents.


Q: Why is it important to tell my doctor about all my vitamins before starting Diergo?

Official patient information advises informing a healthcare provider of all medicines, including vitamins, supplements, and herbal products. This is important because some supplements, particularly herbal products, may interact with the drug’s metabolism.


Q: How does being on Diergo affect blood test results?

The patient information section of regulatory documents notes that blood tests may be required for monitoring during the course of treatment. This is part of the precautionary measures used to check for any potential, unwanted effects of the medicine.

How should Diergo be stored and disposed of?

The official labeling for Diergo (Dihydroergotamine) specifies mandatory conditions to ensure product integrity and safe use.

Required Storage Conditions

Condition Regulatory Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C); do not refrigerate or freeze.
Protection Keep the product in the original container and outer carton to protect it from light and excess heat.
Integrity Check Do not use the medicine if the solution is discolored, cloudy, or contains visible particles, or if the expiration date has passed.

Handling and Disposal

All medicinal products must be stored out of the sight and reach of children. For disposal, unused or expired Diergo must be discarded according to local regulatory requirements to prevent environmental contamination. Do not dispose of the medicine in wastewater or household trash unless directed by local authorities or the product label. Sharps (needles or autoinjectors) must be disposed of in a puncture-resistant container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Diergo found in:

A-Z Index: